If January is anything to go by, it’s going to be an incredibly busy year in the psychedelics space. In the last week alone we learned of a new fast-track designation for MAPS’ MDMA-assisted therapy for PTSD in the UK; a new company that’s seeking to “control” the supply of peyote in Canada; the FDA released a hold on MindMed’s LSD for generalised anxiety disorders study…
